The intake, as well as serum and urinary concentrations, of phytoestrogens is high in countries where incidence of prostate cancer is low, suggesting a chemopreventive role for phytoestrogens. Their significance could be explained by the ability to antagonize the action of more potent endogenous estrogens in initiation or promotion of tumor formation. We have studied estrogenicity and antiestrogenicity of dietary soy and two phytoestrogens, coumestrol and daidzein, in our neoDES mouse model for the study of prostatic neoplasia. Soy was chosen because it is rich in phytoestrogens, is widely used in Oriental diets, and has antiestrogenic and anticarcinogenic properties in the neoDES mouse when given from fertilization onward. In short-term tests with adult animals, no evidence for estrogenicity or antiestrogenicity (capability to antagonize the action of 1 7,B-estradiol) of soy was found when development of epithelial metaplasia and expression of c-fos protooncogene in prostate were used as end points of estrogen action. Estrogenic activity of coumestrol and daidzein on c-fos expression was subtle. Coumestrol, either given alone or in combination with 17,B-estradiol, had no effect on development of epithelial metaplasia. These marginal or missing effects in adult males could be interpreted by assuming that the neonatal period is more critical for estrogenic or antiestrogenic action of soy and phytoestrogens. Once initiated, estrogen-related lesions would develop spontaneously. Alternatively, the chemopreventive action of soy is not due to antiestrogenicity of soyderived phytoestrogens.
Introduction
Dietary soy has chemopreventive properties in several animal models for cancers (1) (2) (3) . There is also suggestive evidence that dietary soy (tofu) is chemopreventive in human prostate cancer (4) . Using the developmentally estrogenized mouse model (5, 6) , we have shown that the estrogenrelated inhibition of prostatic growth is reduced and the development of dysplastic changes is delayed in the prostate when the animals are kept on soy-containing feed from fertilization onward (7) . Both the number of animals showing dysplasia and This paper was presented at the Symposium on Estrogens in the Environment, III: Global Health 7W estradiol. also the severity of the alterations in dysplastic epithelium were lower in animals given soy. Morphologically the dysplastic lesions in the prostate of neoDES animals are similar to prostatic intraepithelial neoplasia (PIN) in human prostate (8) . Although no progression to carcinomas with invasion of surrounding tissues or metastasis could be demonstrated, the morphological changes and increased expression of protooncogenes in developmentally estrogenized mice suggest an increased potential for benign and malignant growth (Table 1) .
Soy is rich in phytoestrogens, weakly estrogenic nonsteroidal compounds. Their urinary excretion (particularly that of isoflavones) correlates with the ingestion of soy in our animal experiments (7) . In humans, urinary excretion and serum concentrations of phytoestrogens are higher in countries where the incidence of prostate cancer is low (9, 10) . This suggests that phytoestrogens may account for the chemopreventive action of soy in prostate carcinogenesis. Figure 1A ,B) When adult neoDES animals were kept on a soy-containing diet for 10 or 21 days after castration, no signs of squamous epithelial metaplasia could be observed. Soy feeding did not prevent the metaplastic reaction induced by 17 3-estradiol implants ( Figure 1C,D) .
Coumestrol (50 pg per day for 7 days given sc) did not induce squamous metaplasia in neoDES animals. Neither did it inhibit the metaplastic reaction induced by 1 71B-estradiol injections (Figure 1 E,F) . Thus, based on squamous epithelial metaplasia, there is no evidence that either coumestrol or dietary soy are estrogenic or antiestrogenic.
Induction ofc-JbsExpression 17J-Estradiol induced the expression of cfos in neoDES mice given a soy-free diet.
After the sc injection of 170-estradiol (100 pg/animal) the increased expression was evident in the prostatic urethra and coagulating glands at 3 to 12 hr after injection ( Figure 2) . Soy given to neoDES animals for 1 week before 17,B-estradiol injection had no effect on the expression. Further, coumestrol and daidzein in a dose of 200 pg/animal sc showed weak estrogenic action (Figure 2 ), but there is no evidence that soy acts as an antiestrogen based on the induction of c-fos expression. (13) . In the corresponding feeding experiment with the male mouse, the sizes of the sex accessory glands were reduced but the differences were not statistically significant (7) . Coumestrol, one of the most potent phytoestrogens, was also incapable of inducing metaplastic transformation in neonatally estrogenized mice; as documented earlier, it did not inhibit the prostatic growth when administered to normal adult rats (13) . However, when the induction of the expression of estrogen-responsive gene, c-fos (one of the immediate early genes in mitosis) in adult neoDES mice was used as an end point, both coumestrol and daidzein showed weak estrogenlike activity. Also in rat uterus the antiestrogen tamoxifen was shown to induce a weak response in c-fos expression (14) . This weak estrogenlike (or antiestrogenlike) effect is induced by phytoestrogen doses comparable to the amounts ingested by laboratory rodents in daily soy-based feed (15) and may therefore be of significance for the effects associated with the high intake of dietary soy.
The weak estrogenicity of coumestrol seen in the adult male is again contradictory with the findings in female rodents. It is very well documented that coumestrol is a potent estrogen in the developing female reproductive tract. It had DES-like effects in the neonatal female mouse (16) and promoted uterine growth in immature rats when given in doses (per body weight) similar to those we used (15, (17) (18) (19) . In adult ovariectomized rats, coumestrol showed partial estrogen agonism; it was uterotrophic but did not induce ovum implantation in mated, ovariectomized gestagen-maintained animals (20) . The conflicting findings on the hormonal potency of soy or coumestrol cannot yet be explained, but they could be due to sex-or age-related differences in the uptake or metabolism of phytoestrogens.
It is also intriguing that in adult male mice soy did not block the estrogeninduced metaplastic transformation or expression of c-fos protooncogene, and coumestrol did not inhibit the development of metaplasia in 17p-estradiol-treated animals. This is in conflict with the idea of the antiestrogenicity of soy seen as reduction of the growth inhibition of the prostate and prevention of dysplastic development after neonatal estrogenization and the reduction of the estrogen-induced growth of immature uterus (7) . One could interpret these findings by assuming that in males the neonatal or prepubertal period would be more critical for estrogen and antiestrogen actions. Once initiated, the estrogen-related lesions would develop spontaneously.
It is not easily concievable how soy or phytoestrogens could antagonize the estrogen action at the target cells. Phytoestrogens (coumestrol, daidzein, genistein) are clearly estrogen agonists in breast cancer cells in vitro and act through the estrogen receptor (ER)-mediated mechanisms (21, 22) . Phytoestrogens with high binding affinities for estrogen receptor are also most active biologically (e.g., they enhance cell proliferation) (23) . Phytoestrogens are supposed to act as antiestrogens by competing with more potent endogenous estrogens for the binding to ER. Dietary estrogens representing three structurally different groups (coumestans, isoflavonoids, and resorcyclic acid lactones) had additive effects with 17p-estradiol in the presence of the concentration giving submaximal stimulation, and none of the phytoestrogens we studied (at concentrations below 1 PM) reduced the proliferation rate of breast cancer cells, i.e., had antiestrogenic effects in the presence of 17p-estradiol (22 Moreover, the possibility remains that the chemopreventive action of soy is not due to the antiestrogenicity of soy-derived phytoestrogens. At very high concentrations, phytoestrogens are reported to have effects not related to estrogen action. Genistein, an isoflavonoid phytoestrogen, is a potent inhibitor of both estrogen receptor negative and positive breast cancer cells (27) and of tyrosine protein kinase activity of several growth factor receptors and oncogenes that may be associated with tumor cell growth (28) . Further, the inhibition of DNA topoisomerase II has been suggested as an alternative mechanism for the action of isoflavones (29) . Genistein is also an inhibitor of angiogenesis, which may partly explain the possible antitumor activity of phytoestrogens (30) . The relevance of these mechanisms for understanding the possible antiestrogenic action of soy or soy-derived estrogens in the male mouse is not known. It is noteworthy that soy had no general inhibitory effect on prostatic growth in neonatally untreated animals (7) .
In addition to phytoestrogens, soybeans contain several other potential anticarcinogenic agents such as protease inhibitors, phytosterols, saponins, and inositol hexaphosphate (1,31); their possible roles as chemopreventive agents cannot be excluded in the present model.
